Blog Category

Press Releases

Biophytis Announces Temporary Trading Halt of its Shares and Share Warrants on Euronext Growth

,

/

10 February 2021

Biophytis Announces Trading Resumption of its Ordinary Shares and Share Warrants on Euronext

,

/

10 February 2021

Biophytis Announces the Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”)

,

/

3 February 2021

Biophytis Announces the Launch of its Proposed Public Offering and Nasdaq Listing

,

/

3 February 2021

Biophytis Announces Public Filing of a Registration Statement for Proposed Initial Public Offering in the United-States

,

/

20 January 2021

Biophytis receives DMC recommendation for starting recruitment for Part 2 of its Phase 2-3 COVA study in COVID-19

,

/

19 January 2021

Biophytis Announces Plan to Publicly File Later Today Registration Statement for Proposed Initial Public Offering in the United States

,

/

19 January 2021

Biophytis to Participate in Upcoming Investor & Partnering Conferences During J.P. Morgan Week 2021

,

/

7 January 2021

Last patient completes final visit in SARA-INT, a Phase 2 clinical trial evaluating the efficacy of Sarconeos (BIO101) in the treatment of sarcopenia

,

/

16 December 2020

Biophytis Presents SARA-OBS study results at the Annual Conference of The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD)

,

/

14 December 2020

First Patient Enrolled in France in COVA, an International Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure

,

/

11 December 2020

Upcoming Potential Value Generating Milestones

,

/

3 December 2020